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Cytochrome P450 2C19 681G>A
Polymorphism and High On-Clopidogrel
Platelet Reactivity Associated With Adverse 1-Year
Clinical Outcome of Elective Percutaneous Coronary
Intervention With Drug-Eluting or Bare-Metal Stents
Dietmar Trenk, PHD,* Willibald Hochholzer, MD,* Martin F. Fromm, MD,† Ligia-Emilia Chialda, MD,†
Andreas Pahl, PHD,† Christian M. Valina, MD,* Christian Stratz, MD,* Peter Schmiebusch, MD,*
Hans-Peter Bestehorn, MD,* Heinz Joachim Büttner, MD,* Franz-Josef Neumann, MD*
Bad Krozingen and Erlangen, Germany
Objectives We investigated whether the loss of function CYP2C19 681GA *2 polymorphism is associated with high
(14%) residual platelet aggregation (RPA) on clopidogrel and whether high on-clopidogrel RPA impacts clinical
outcome after elective coronary stent placement.
Background The cytochrome P450 (CYP)–dependent conversion of clopidogrel to its active metabolite may contribute to the
variability in antiplatelet effect of clopidogrel.
Methods The study included 797 consecutive patients undergoing percutaneous coronary intervention, who were
followed-up for 1 year. Adenosine-diphosphate–induced (5 mol/l) RPA was assessed after a 600-mg loading
dose and after the first 75-mg maintenance dose of clopidogrel before discharge. CYP2C19 genotype was ana-
lyzed by real-time polymerase chain reaction.
Results Of the patients included, 552 (69.3%) were CYP2C19 wild-type homozygotes (*1/*1) and 245 (30.7%) carried at
least one *2 allele. Residual platelet aggregation at baseline did not differ significantly between genotypes. On clopi-
dogrel, RPA was significantly (p 0.001) higher in *2 carriers than in wild-type homozygotes (23.0% [interquartile
range (IQR) 8.0% to 38.0%] vs. 11.0% [IQR 3.0% to 28.0%] after loading; 11.0% [IQR 5.0% to 22.0%] vs. 7.0% [IQR
3.0% to 14.0%] at pre-discharge). Between *2 carriers and wild-type homozygotes, we found significant (p 0.001)
differences in the proportion of patients with RPA14%, both after loading (62.4% vs. 43.4%) and at pre-discharge
(41.3% vs. 22.5%). Residual platelet aggregation14% at pre-discharge incurred a 3.0-fold increase (95% confi-
dence interval 1.4 to 6.8; p  0.004) in the 1-year incidence of death and myocardial infarction.
Conclusions Patients carrying at least one CYP2C19*2 allele are more prone to high-on clopidogrel platelet reactivity, which
is associated with poor clinical outcome after coronary stent placement (Effect of Clopidogrel Loading and Risk
of PCI [EXCELSIOR]; NCT00457236). (J Am Coll Cardiol 2008;51:1925–34) © 2008 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.12.056I
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(fter administration of clopidogrel, high on-treatment
latelet reactivity is associated with increased risk of adverse
vents after percutaneous coronary intervention (PCI) with
tent placement. Consistently, this has been shown by both
he EXCELSIOR (Impact of Extent of Clopidogrel-
rom the *Herz-Zentrum Bad Krozingen, Bad Krozingen, and the †Institute of
xperimental and Clinical Pharmacology and Toxicology, University of Erlangen-
uremberg, Erlangen, Germany. This study was supported by a grant from the
erz-Zentrum, Bad Krozingen, Germany.i
Manuscript received September 10, 2007; revised manuscript received November
0, 2007, accepted December 10, 2007.nduced Platelet Inhibition During Elective Stent Implan-
ation on Clinical Event Rate) (1) and the RE-CLOSE
Low REsponsiveness to CLOpidogrel and Sirolimus- or
aclitaxel-Eluting StEnt Thrombosis) trials (2), as well as
See page 1935
y a number of smaller studies (3–12). Specifically, in the
XCELSIOR trial we demonstrated a more than 6-fold
ncrease in the 30-day risk of death, myocardial infarction
MI), and target vessel reintervention after stent placement,
f adenosine diphosphate (ADP)-induced (5 mol/l) resid-
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CYP2C19 and Antiplatelet Effect of Clopidogrel May 20, 2008:1925–34ual platelet aggregation (RPA)
after a 600-mg loading dose of
clopidogrel was 14% (1). High
on-treatment platelet reactivity
(RPA 14%) was associated with
older age, obesity, and diabetes
mellitus. In addition, the propen-
sity for high on-treatment platelet
reactivity may be genetically deter-
mined, an issue that was not ad-
dressed in the initial report on the
EXCELSIOR trial.
The prodrug clopidogrel has to
be converted into the active me-
tabolite (13,14) that selectively and
irreversibly binds to the P2Y12 re-
eptor on the platelet membrane (15–18). Conversion is
chieved by the highly polymorphic hepatic cytochrome P450
CYP) system in a 2-step process. In 28 healthy subjects, Hulot
t al. (19) investigated polymorphisms of CYP 2C19, 2B6,
A2, and 3A4/5 with known functional consequences on
nzyme activity and a minor allele frequency higher than 5% in
aucasians. Among the polymorphisms investigated, only the
oss-of-function CYP2C19 681GA polymorphism (*2) was
ssociated with blunted antiplatelet responses to clopidogrel. In
he gene encoding for CYP2C19, the single nucleotide poly-
orphism 681GA (rs4244285) in exon 5, mapped to the
ong arm of chromosome 10 (10q24.1–q24.3) (20), encodes
or a cryptic splice variant resulting in no enzyme activity in
ivo (21,22). The role of the *2 polymorphism of CYP2C19 in
ealthy volunteers was subsequently confirmed by a second
tudy (23). In a study of 79 patients with coronary artery
isease (24), however, the investigators were unable to dem-
nstrate an impact of the CYP2C19 genotype on the antiplate-
et effect of a 600-mg bolus dose. Thus, in the clinical setting,
he role of the CYP2C19*2 loss-of-function polymorphism is
urrently unclear.
Based on these findings, we addressed the question whether
n the EXCELSIOR cohort the loss-of-function CYP2C19*2
olymorphism was associated with high on-treatment platelet
eactivity (RPA14%) after administration of clopidogrel. To
orroborate the clinical relevance of the EXCELSIOR trial
efinition of high on-treatment platelet reactivity, we ex-
anded the clinical follow-up to 1 year and assessed the relation
etween RPA 14% at pre-discharge and 1-year incidence of
eath and MI. We also analyzed various other platelet function
ests, including light transmission aggregometry after stimula-
ion with 20 mol/l ADP and surface expression of activation-
ependent platelet receptors to confirm a potential impact of
YP2C19*2 polymorphism on platelet function after
lopidogrel.
ethods
tudy selection and interventions. The current study is a
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
CI  confidence interval
CYP  cytochrome P450
GP  glycoprotein
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PCR  polymerase chain
reaction
RPA  residual platelet
aggregationre-specified analysis of the EXCELSIOR cohort. Details tf the EXCELSIOR study design have been published
reviously (1). Briefly, patients undergoing elective coronary
tent placement after pre-treatment with 600 mg of clopi-
ogrel and aspirin (100 mg per day for at least 5 days) were
ligible for this prospective, single-center study conducted
n a referral center setting in Germany. We did not include
atients with acute MI according to the European Society
f Cardiology/American College of Cardiology consensus
ocument (25); patients on chronic oral anticoagulation or
hienopyridine treatment within the last 2 weeks before
dmission; patients with contraindications to aspirin, clopi-
ogrel, or heparin; and patients with cancer or hemodialysis.
he study was approved by the ethics committee of the
edical faculty of the University of Freiburg, Germany. All
atients gave written informed consent.
Before PCI, all patients received a loading dose of 600 mg
f clopidogrel. Percutaneous coronary intervention with
tent placement was performed as described previously
1,26). The choice of stent type, bare-metal stent or
aclitaxel- or sirolimus-eluting stent, was left to the opera-
or’s discretion. All patients received an intra-arterial dose of
00 to 140 U/kg heparin; glycoprotein (GP) IIb/IIIa
nhibitors were not allowed except for bail-out. After PCI,
ll patients received aspirin (100 mg per day) lifelong and
lopidogrel (75 mg per day) for 30 days after placement of
are-metal stents or for 6 months after placement of at least
drug-eluting stent.
Baseline blood samples were drawn before administration
f clopidogrel for platelet function assays using tubes con-
aining 3.8% sodium-citrate (Sarstedt AG, Nuembrecht,
ermany). Blood for genomic deoxyribonucleic acid
DNA) extraction was sampled using tubes containing 1.2
o 2 mg potassium ethylenediaminetetraacetic acid per
illiliter of blood (Sarstedt AG). We obtained the second
lood sample at the time of catheterization before admin-
stration of heparin or contrast medium and a third pre-
ischarge sample at day 1 after loading 2 to 4 h after intake
f the first maintenance dose of clopidogrel. Samples were
rocessed within 1 h after blood drawing.
We performed a phone interview at 30 days and after 12
onths. Thirty-day follow-up was complete in all patients
nd 12-month follow-up in all but 7 patients (99.1%). For
atients reporting cardiac symptoms, at least 1 clinical and
lectrocardiographic examination was performed in the
utpatient clinic or by the referring physician. The infor-
ation derived from contingent hospital readmission
ecords or provided by the referring physician or by the
utpatient clinic was entered into the computer database.
latelet function assays. Platelet aggregation was assessed
y light transmission aggregometry using a 4-channel Bio/
ata PAP4 aggregometer (Mölab, Langenfeld, Germany),
s described previously (26). Blood for platelet aggregation
as available from all patients at baseline and at cardiac
atheterization. Platelet function could not be determined in
7 patients pre-discharge. The reasons were: discharge earlier
han 24 h after PCI in 32 patients, peri-interventional admin-
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May 20, 2008:1925–34 CYP2C19 and Antiplatelet Effect of Clopidogrelstration of abciximab in 2 patients, and transfer to the
ntensive care unit for large MI in 3 patients. Platelet-rich
lasma was prepared by centrifugation of citrated venous blood
t 750 g for 2 min and adjusted to 275 to 325  109
hrombocytes/l by dilution with autologous platelet-poor
lasma. Residual platelet aggregation was determined as light
ransmission in platelet-rich plasma 5 min after addition of
DP (Sigma, Munich, Germany) at final concentrations of 5
nd 20 mol/l. Percentage of maximal light transmission was
alculated using platelet-poor plasma from the same patient as
eference (100% aggregation). The coefficient of variation of
ur optical aggregometry assay is 6.1% (26).
Adenosine diphosphate-induced surface expression of
-selectin (CD62P), activated GP IIb/IIIa (PAC-1),
D40L, CD41, and CD63 was determined by triple color
ow cytometry as previously described (26). Platelets in
hole blood were stained with 2 antibody mixtures contain-
ng either fluorescein-isothiocyanate–tagged PAC-1 (acti-
ated GP IIb/IIIa receptors), phycoerythrin-tagged anti-
D62P (P-selectin), and phycoerythrin-cyanin 5.1–tagged
nti-CD41 (total GP IIb/IIIa receptors) monoclonal anti-
odies or phycoerythrin-tagged anti-CD40L, fluorescein-
sothiocyanate–tagged anti-CD63, and anti-CD41 monoclo-
al antibodies (PAC-1 by Becton-Dickinson, Heidelberg,
ermany, all other antibodies by Beckman Coulter, Krefeld,
ermany). Platelets were incubated with the antibodies and
DP at a final concentration of 20 mol/l for 30 min.
hereafter, 300 l of para-formaldehyde 1% was added for
xation. A 4-channel flow cytometer equipped with a 488-nm
rgon laser (FACSCalibur, Becton Dickinson, Heidelberg,
ermany) was used. Platelets were identified in whole blood
y size, and a platelet-specific monoclonal antibody (CD41),
nd 10,000 events from each sample were analyzed. The mean
hannel of fluorescence intensity was taken as a measure for
ntibody binding, and thus antigen surface exposure.
enotyping by TaqMan polymerase chain reaction
PCR). Genomic DNA was extracted from 200 l peripheral
otassium ethylenediaminetetraacetic acid-anticoagulated blood
ith the Flexigene Kit (QIAGEN, Hilden, Germany) according
o the manufacturer’s instruction. After extraction, the concentra-
ion of DNA was measured photometrically and DNA was
iluted to a concentration of 5 mg/l. CYP2C19*2 (681GA;
s4244285) was genotyped using a commercially available vali-
ated Drug Metabolism Genotyping Assay (Applied Biosystems,
rankfurt, Germany; part no. C_25986767_70). Amplification
as performed in a final volume of 5 l containing 1 l of DNA
olution of a concentration of 5 mg/l, 0.25 l primer mix, 2.5 l
PCR Master Mix (Abgene, Hamburg, Germany), and 3.75 l
f distilled water. Reaction mixtures were loaded into 384 well
lates and placed in an ABI Prism Sequence Detector 7900
Applied Biosystems). Polymerase chain reaction conditions were
s follows: initial denaturation at 95°C for 10 min, followed by 45
ycles of denaturation (92°C for 30 s), annealing and extension in
step (60°C for 60 s). After PCR, fluorescence yield for the 2
ifferent dyes was measured and presented in a 2-dimensional
raph. mutcomes. In the analysis of the impact of the CYP2C19*2
olymorphism on platelet reactivity after administration of
lopidogrel, the proportion of patients achieving an RPA
14% after stimulation with 5 mol/l ADP was our
rimary outcome measure. The primary analysis of the
XCELSIOR trial had revealed that this threshold delin-
ates subsets of patients at increased 30-day risk of major
dverse cardiac events. Compared with maximal light trans-
ission used in some of the previous studies (27–29), RPA
s considered to more closely resemble P2Y12-dependent
esponses and comprises both formation and stability of
ggregates.
To further corroborate the clinical impact of an RPA
14%, we tested the hypothesis that an RPA 14% after
he first maintenance dose at pre-discharge was associated
ith an increased risk of death and MI during 1-year
ollow-up as compared with an RPA 14%. We therefore
nalyzed the cumulative incidence of death from any cause
nd nonfatal MI from the first maintenance dose to 12
onths after coronary intervention, thus excluding acute
rocedure-related events that had been addressed in the
rimary analysis. The diagnosis of MI was made according
o the European Society of Cardiology/American College of
ardiology consensus document and based on new rise in
roponin T 0.03 mg/l associated with typical symptoms
nd/or typical electrocardiogram changes and/or typical
ngiographic findings (25). We also assessed the incidence
f stent thrombosis according to the Academic Research
onsortium criteria (30). All events were classified and
djudicated by 2 physicians not involved in the follow-up
rocess and blinded to the results of the platelet function
ata.
tatistical analysis. To compare the proportion of patients
ith RPA 14% between carriers of the CYP2C19*2 allele
nd wild-type homozygotes, we used the chi-square test and
alculated adjusted and unadjusted odds ratios from logistic
egression models. In the adjusted models, we included
aseline variables (Table 1) with a difference between
arriers of the CYP2C19*2 allele and wild-type homozygotes
t a value of p  0.20. The Komolgorov-Smirnov test
evealed that the platelet function variables had a non-
ormal distribution. Therefore, we report platelet function
ariables as median (interquartile range) and tested differ-
nces between CYP2C19 genotypes by the Mann-Whitney
test for 2 groups or the Kruskal-Wallis-H test for 3
roups. To corroborate these analyses, we also performed
-way analysis of variance (ANOVA), which always con-
rmed significant results of non-parametric testing.
For our main analysis with regard to the impact of
re-discharge RPA on outcome, we assessed the difference
n the incidence of the primary end point between the strata
efined by pre-discharge RPA by 2-sided testing based on
he log-rank statistic and a significance level of alpha 
.05. Cumulative event rates were calculated and graphically
escribed according to the Kaplan-Meier method. To sum-
arize differences in the primary end point between the
s
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CYP2C19 and Antiplatelet Effect of Clopidogrel May 20, 2008:1925–34trata defined by pre-discharge RPA, we derived hazard
atios with associated 95% confidence intervals (CIs) from
aseline Demographic and Clinical Characteristics of the Study Co
Table 1 Baseline Demographic and Clinical Characteristics of t
According
Entire Cohort
(n  802)
RPA <14%
(n  548)
Age (yrs) 66.4 9.1 65.7 9.2
Women 175 (21.8) 118 (21.5)
Time from loading dose to PCI (h) 6.3 11.2 6.1 11.0
Active smoker 87 (10.8) 62 (11.3)
Arterial hypertension 660 (82.3) 440 (80.3)
Diabetes mellitus 199 (24.8) 116 (21.2)
Total cholesterol (mmol/l) 5.1 1.2 5.2 1.2
Body mass index (kg/m2) 27.7 3.9 27.4 3.8
Platelets (109/l) 216 56 219 55
Aspirin 802 (100.0) 548 (100.0)
Beta-blockers 555 (69.2) 381 (69.5)
ACE inhibitors 342 (42.6) 223 (40.7)
AT1 antagonists 123 (15.3) 87 (15.9)
Diuretics 270 (33.7) 188 (34.3)
Nitrates 239 (29.8) 156 (28.5)
Any statin 455 (56.7) 305 (55.7)
CYP3A4-metabolized statin 377 (47.0) 250 (45.6)
Verapamil/diltiazem 34 (4.2) 15 (2.7)
Insulin 56 (7.0) 30 (5.5)
Oral antidiabetics 115 (14.3) 64 (11.7)
Previous balloon angioplasty 274 (34.2) 176 (32.1)
Previous CABG 112 (14.0) 71 (13.0)
Previous MI 184 (22.9) 126 (23.0)
Impaired LV function* 286 (35.8) 186 (33.9)
CCS angina class III or IV 199 (24.8) 141 (25.7)
Multivessel PCI 178 (22.2) 132 (24.1)
Number of stents implanted 1.8 1.0 1.8 1.0
Drug-eluting stent implanted 292 (36.4) 211 (38.5)
Number of drug-eluting stents implanted 0.4 0.6 0.4 0.6
AHA/ACC lesion type B2 or C 528 (65.8) 351 (64.6)
Stented segment
Left main coronary artery 18 (2.2) 13 (2.4)
Left anterior descending artery 367 (45.8) 262 (47.8)
Circumflex artery 295 (36.8) 199 (36.3)
Right coronary artery 281 (35.0) 191 (34.9)
Bypass graft 25 (3.1) 18 (3.3)
QCA analysis
Vessel size (mm) 2.85 0.57 2.84 0.57
Before PCI
Minimal luminal diameter (mm) 0.72 0.50 0.73 0.50
Diameter stenosis (%) 74.8 15.9 74.7 15.8
Stenosis length (mm) 10.2 5.2 10.4 5.1
Balloon size (mm) 3.2 0.5 3.2 0.5
Inflation pressure (atm) 13.8 2.8 13.8 2.7
After PCI
Minimal luminal diameter (mm) 2.76 0.46 2.77 0.46
Diameter stenosis (%) 9.3 6.6 8.8 6.5
Stented length (mm) 21.1 11.8 21.1 11.3
ata are expressed as mean SD or number of patients (percentage). The p values were determin
14% and RPA 14% or between CYP2C19 genotypes. CYP3A4-metabolized statin summarizes
ACC  American College of Cardiology; ACE  angiotensin-converting enzyme; AHA  Amer
ardiovascular Society; LV  left ventricular; MI  myocardial infarction; PCI  percutaneous corhe Cox proportional hazards model. To assess the interac- sion of drug-eluting stents with pre-discharge RPA and to
djust for potential confounders, we performed Cox regres-
According to RPA Respective CYP2C19 Genotype
tudy Cohort According to RPA Respective CYP2C19 Genotype
A at Pre-Discharge According to CYP2C19 Genotype
A >14%
 217) p Value
*1/*1
(n  552)
*1/*2 or *2/*2
(n  245) p Value
.1 8.9 0.001 66.1 9.2 66.9 8.9 0.245
7 (21.7) 0.969 123 (22.3) 52 (21.2) 0.739
.4 0.8 0.510 5.9 10.1 6.9 13.1 0.275
0 (9.2) 0.398 52 (9.4) 35 (14.3) 0.042
8 (86.6) 0.039 459 (83.2) 197 (80.4) 0.349
0 (32.3) 0.001 139 (25.2) 59 (24.1) 0.740
.1 1.1 0.387 5.1 1.2 5.1 1.1 0.828
.3 3.9 0.004 27.8 4.0 27.4 3.4 0.179
1 53 0.074 214 53 220 58 0.203
7 (100.0) 1.000 552 (100.0) 245 (100.0) 1.000
7 (67.7) 0.631 381 (69.0) 170 (69.4) 0.918
1 (46.5) 0.140 236 (42.8) 102 (41.6) 0.768
1 (14.3) 0.583 76 (13.8) 47 (19.2) 0.051
9 (31.8) 0.508 177 (32.1) 90 (36.7) 0.197
4 (34.1) 0.126 164 (29.7) 74 (30.2) 0.888
8 (59.0) 0.402 310 (56.2) 142 (58.0) 0.636
8 (49.8) 0.300 257 (46.6) 118 (48.2) 0.675
7 (7.8) 0.002 21 (3.8) 12 (4.9) 0.475
1 (9.7) 0.036 39 (7.1) 17 (6.9) 0.949
4 (20.3) 0.002 71 (12.9) 43 (17.6) 0.081
7 (40.1) 0.036 199 (36.1) 75 (30.6) 0.136
6 (16.6) 0.192 81 (14.7) 29 (11.8) 0.284
1 (23.5) 0.880 126 (22.8) 56 (22.9) 0.992
6 (39.6) 0.138 192 (34.8) 89 (36.3) 0.674
6 (21.2) 0.189 141 (25.5) 56 (22.9) 0.417
2 (19.4) 0.159 117 (21.2) 61 (24.9) 0.247
.8 1.1 0.736 1.8 1.0 1.9 1.1 0.296
0 (32.3) 0.106 197 (35.7) 94 (38.4) 0.469
.4 0.7 0.382 0.4 0.6 0.4 0.6 0.554
8 (68.8) 0.234 380 (69.0) 149 (60.8) 0.025
4 (1.8) 0.655 10 (1.8) 8 (3.3) 0.202
2 (42.4) 0.176 255 (46.2) 112 (45.7) 0.900
1 (37.3) 0.793 193 (35.0) 98 (40.0) 0.173
7 (35.5) 0.869 192 (34.8) 89 (36.3) 0.674
7 (3.2) 0.967 19 (3.4) 5 (2.0) 0.285
6 0.58 0.720 2.83 0.56 2.91 0.58 0.053
2 0.50 0.841 0.72 0.50 0.74 0.49 0.639
.0 16.2 0.775 74.7 16.2 75.0 15.2 0.819
.7 5.0 0.112 10.2 5.3 10.1 4.8 0.719
.2 0.5 0.624 3.2 0.5 3.2 0.4 0.148
.8 2.6 0.979 13.8 2.8 13.9 2.7 0.789
3 0.45 0.308 2.74 0.46 2.80 0.46 0.107
.1 6.6 0.014 9.3 6.56 9.1 6.6 0.723
.8 12.1 0.781 21.5 11.8 20.3 11.9 0.176
-way analysis of variance or chi-square between patients with residual platelet aggregation (RPA)
s treated with atorvastatin, lovastatin, or simvastatin. *Left ventricular ejection fraction 55%.
art Association; AT  angiotensin; CABG  coronary artery bypass grafting; CCS  Canadian
tervention; QCA  quantitative coronary angiography; RPA  residual platelet aggregation.hort
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May 20, 2008:1925–34 CYP2C19 and Antiplatelet Effect of Clopidogrelultivariable models included demographic, clinical, and
ngiographic variables (Table 1) with a difference between
he 2 strata defined by pre-discharge RPA at a value of p 
.20.
If not stated otherwise, discrete variables are reported as
ounts (percentages) and continuous variables as mean 
tandard deviation. For discrete variables, we tested differ-
nces between groups with the chi-square test or Fisher
xact test when expected cell sizes were less than 5. To
ompare continuous variables, we used 1-way ANOVA. In
he 2-sided test, a p value0.05 was regarded as significant.
e used the SPSS software package, version 14 (SPSS Inc.,
hicago, Illinois) for all statistical analyses.
The sample size of the EXCELSIOR study was based on
he power calculation for the 30-day primary end point as
ublished previously (1).
esults
YP2C19 genotyping results. CYP2C19 genotype could
e determined in 797 patients out of the whole cohort of
02 patients enrolled in the EXCELSIOR study. Five
atients refused to consent to blood sampling for genetic
nvestigations.
Of the 797 patients, 552 (69.3%) were CYP2C19 wild-
ype homozygotes (*1/*1), 228 (28.6%) were CYP2C19
*1/*2) heterozygote, and 17 (2.1%) were homozygous with
espect to the *2 allelic variant. This corresponds to allele
requencies of 83.6% for CYP2C19*1 (G) and 16.4% for
YP2C19*2 (A), which is consistent with the known allele
requency in Caucasians. The distribution of the genetic
ariants did not deviate significantly from the Hardy-
einberg equilibrium (p  0.20). Due to the low numbers
f *2 homozygotes, we based most of our analyses on the
omparison between carriers of the CYP2C19*2 allele and
ild-type homozygotes.
Baseline demographic and clinical characteristics of the
tudy population according to their CYP2C19 genotype are
ummarized in Table 1. There were no significant differ-
nces between wild-type homozygous patients and patients
ith the allelic variant CYP2C19*2 except a slightly higher
roportion of active smokers and a slightly lower proportion
f patients with type B2 or C coronary lesions according to
he American Heart Association/American College of Car-
iology definitions in the cohort carrying the *2 allelic
ariant of CYP2C19.
YP2C19 polymorphism and on-clopidogrel platelet re-
ctivity. Both at the time of PCI after the 600-mg loading
ose of clopidogrel and at pre-discharge after the first
aintenance dose, carriers of the CYP2C19*2 allele were
ignificantly more likely than wild-type homozygotes to
iss the level of RPA 14% after stimulation with 5
mol/l ADP (Fig. 1). At pre-discharge, 41.3% of the
arriers of the CYP2C19*2 allele, but only 22.5% of wild-
ype homozygotes had an RPA 14% (p  0.001); at the
ime of PCI the respective proportions were 62.4% and d3.3% (p  0.001). Thus, at pre-discharge the unadjusted
dds ratio for RPA 14% was 2.43 (95% CI 1.74 to 3.38;
 0.001) in carriers of the CYP2C19*2 allele as compared
ith wild-type homozygotes and it was 2.18 (95% CI 1.60
o 2.97; p  0.001) at the time of PCI (Fig. 1). Similar
esults were obtained after adjustment for pertinent covari-
bles, including clinical characteristics (active smoker, body
ass index, hypertension, previous PCI), drug therapy
angiotensin-1 blockers, diuretics, oral antidiabetics), or
ngiographic parameters (American Heart Association/
merican College of Cardiology coronary lesion type B2 or
, stenting in circumflex artery, vessel size, balloon size,
inimal lumen diameter after PCI, stented length) (Fig. 1).
These findings could be attributed to a significantly
ttenuated platelet inhibition by clopidogrel in carriers of
he CYP2C19*2 allele as compared with wild-type homozy-
otes (Fig. 2, Table 2). While baseline RPA was similar
rrespective of CYP2C19 genotype, RPA induced by 5
mol/l ADP differed significantly between CYP2C19 geno-
ypes, both after the 600-mg loading dose of clopidogrel at
he time of PCI and after the first maintenance dose at
re-discharge. At both time points, carriers of the
YP2C19*2 allele had a significantly higher RPA than
ild-type homozygotes (Table 2).
As shown in Table 2, we obtained similar results when
latelet aggregation was induced by 20 mol/l ADP. The
ssociation between the allelic variant CYP2C19*2 and
igher on-clopidogrel platelet reactivity was also confirmed
y flow cytometry of the surface expression of activation-
Figure 1 ORs for High On-Clopidogrel Platelet
Reactivity According to CYP2C19*2 Genotype
Odds ratios (ORs) with 95% confidence intervals for residual platelet aggrega-
tion (RPA) 14% after stimulation of platelet-rich plasma with adenosine
diphosphate 5 mol/l comparing patients (Pts) carrying at least 1 CYP2C19
*2 allelic variant with wild-type homozygotes before percutaneous coronary
intervention (PCI) and pre-discharge with and without adjustment for baseline
variables (Table 1), with a difference between carriers of the CYP2C19*2 allele
and wild-type homozygotes at a value of p  0.20. Odds ratios and p values
were derived from logistic regression models.ependent proteins after stimulation with ADP 20 mol/l,
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CYP2C19 and Antiplatelet Effect of Clopidogrel May 20, 2008:1925–34hich could be analyzed in 699 patients. No significant
ifferences in the expression of any of the surface proteins
nalyzed were found at baseline (Table 2). During PCI,
owever, surface expression of P-selectin, activated GP
Ib/IIIa, CD63, as well as CD40L was significantly higher
n patients with the *2 allele than in wild-type homozygous
atients indicating an attenuated antiplatelet effect of clo-
idogrel in carriers of the CYP2C19*2 allele as compared
ith CYP2C19 *1/*1 patients (Table 2). We obtained
onsistent results at pre-discharge (Table 2).
re-discharge platelet aggregation and 1-year clinical
utcome. Of the 802 patients of the EXCELSIOR cohort,
re-discharge RPA could be obtained in 765 patients.
re-discharge RPA was14% in 217 patients and14% in
48 patients. Table 1 shows the demographic and baseline
linical characteristics as well as the procedural and angio-
raphic variables in these cohorts stratified with regard to
his cut point in RPA. Compared with the patients with
PA 14%, patients with RPA 14% were significantly
lder, had a significantly higher body mass index, and had a
ignificantly higher residual stenosis after PCI. Likewise,
he proportion of patients with diabetes mellitus, arterial
ypertension, and previous PCI as well as the proportion of
atients being treated with oral antidiabetics, insulin, or vera-
amil/diltiazem was significantly increased in patients with
PA14%, as compared with the patients with RPA14%.
Figure 3 shows the cumulative incidence of death and MI
uring 1-year follow-up. This composite end point was
eached by 13 of 217 patients (6.0%) with pre-discharge
PA 14% and by 11 of 548 patients (2.0%) with RPA
14%. Thus, pre-discharge RPA 14% was associated
ith a hazard ratio for death and MI of 3.0 (95% CI 1.4 to
.8; p 0.004) compared with RPA14%. The excess risk
ssociated with a pre-discharge RPA 14% prevailed after
djustment for baseline and procedural variables, with a
Figure 2 Platelet Aggregation
According to CYP2C19*2 Genotype
Residual platelet aggregation in response to adenosine diphosphate (ADP) 5
mol/in 3 CYP2C19 genotypes at various time points, as indicated below the
columns. The columns represent median with interquartile range. The p value
was determined by Kruskal-Wallis-H test. ns  not significant; other abbrevia-
tions as in Figure 1.ifference between the 2 strata defined by pre-discharge rPA at a value of p  0.20. The corresponding adjusted
azard ratio was 3.7 (95% CI 1.5 to 8.8; p  0.004).
Table 3 shows the incidence of individual cardiac events
n the 2 strata defined by pre-discharge RPA. The difference
etween the 2 strata defined by pre-discharge RPA was
riven by death and large MIs. With the exception of 2
nfarctions in patients without a drug-eluting stent of the
tratum with RPA 14%, all infarctions occurred in areas
ubtended by a treated vessel. Most of the events constitut-
ng the primary end point could be classified as definite,
robable, or possible stent thrombosis (Table 3).
Figure 4 shows the cumulative incidence of the primary
nd point in the 2 subsets defined by stent type stratified by
re-discharge RPA, which was significantly different be-
ween the 4 strata (log-rank p  0.020 for the overall
omparison). In patients who received at least 1 drug-
luting stent, the 1-year incidence of death and MI was
.1% in patients with pre-discharge RPA 14% and 0.9%
n patients with pre-discharge RPA 14%, corresponding
o a hazard ratio for death and MI of 7.8 (95% CI 1.5 to
0.3; p  0.004). Among patients who did not receive a
rug-eluting stent (Fig. 4), the difference in 1-year outcome
etween the 2 strata with respect to death and MI was
maller (5.4% for RPA14% vs. 2.7% for RPA14%) and
id not reach statistical significance (p  0.13). On formal
esting of the interaction of pre-discharge RPA with stent
ype regarding the primary end point, the p for interaction
as 0.10 when added to the Cox regression model including
aseline and procedural variables, with a difference between the
strata defined by pre-discharge RPA at a value of p  0.20.
n this model, the hazard ratio of RPA14% for the primary
nd point was 11.4 (95% CI 2.1 to 61.4; p  0.005).
When we analyzed the 1-year incidence of death and MI
ith respect to the CYP2C19*2 polymorphism, we found 5
2.0%) patients with an event among carriers of the
YP2C19*2 allele and 19 (3.4%) patients with an event
mong wild-type homozygotes (p  0.371). Within the
roup with at least 1 drug-eluting stent, the percentage of
atients with an event was 3.3% (3 of 90) among carriers of
he CYP2C19*2 allele versus 2.1% (4 of 190) among
ild-type homozygotes (p  0.684).
iscussion
ur current study in a large cohort of patients undergoing
lective PCI conveys 2 main messages: 1) due to a substan-
ially attenuated antiplatelet effect of clopidogrel in carriers
f the loss-of-function *2 allelic variant of CYP2C19 as
ompared with wild-type homozygotes, the *2 allelic variant
f CYP2C19 is associated with an almost 2-fold risk of high
n-clopidogrel platelet reactivity; and 2) such high on-
lopidogrel platelet reactivity increases risk of death and MI
uring the first year after elective stent placement by about
-fold. Based on the previously published data from the
XCELSIOR trial, we defined high on-treatment plateleteactivity as RPA after stimulation with 5mol/l ADP14%,
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May 20, 2008:1925–34 CYP2C19 and Antiplatelet Effect of Clopidogrelhich was associated with a more than 6-fold increase in the
0-day risk of death, MI, and urgent target lesion revascular-
zation after elective stent placement. Taken together, the
riginal EXCELSIOR trial data and the current analysis
resent robust evidence that high-on treatment platelet reac-
ivity as defined by RPA 14% exposes patients with elective
CI to a substantially increased risk of cardiac complications,
oth peri-interventionally and during 1-year follow-up.
mpact of CYP2C19 681G>A polymorphism on clopi-
ogrel effect. At the time of PCI after loading with 600 mg
lopidogrel, the proportion of patients with RPA 14% in
arriers of the *2 allele was 19.1 percentage points higher
han in wild-type homozygotes, and the majority (62.4 %)
f carriers of the *2 allele failed to reach an RPA 14%.
latelet Aggregation and Expression of Surface Proteins According
Table 2 Platelet Aggregation and Expression of Surface Protein
CYP2C19 *1/*1 (n  5
Median Interquar
Light transmission aggregometry
RPA ADP 5 mol/l (%)
Baseline 46.0 (36.0–
At cath lab 11.0 (3.0–2
Pre-discharge* 7.0 (3.0–1
% inhibition of RPA ADP 5 mol/l
At cath lab 74.2 (36.1–
Pre-discharge* 83.7 (67.4–
RPA ADP 20 mol/l (%)
Baseline 73.0 (65.0–
At cath lab 35.0 (11.3–
Pre-discharge* 20.0 (8.0–3
% inhibition of RPA ADP 20 mol/l
At cath lab 51.4 (24.2–
Pre-discharge* 73.6 (48.5–
Surface protein expression after stimulation with ADP 20 mol/l (au)
P-selectin (CD62P)
Baseline 109.0 (77.0–
At cath lab 26.0 (13.0–
Pre-discharge* 20.0 (11.0–
Activated GP IIa/IIIb (PAC-1)
Baseline 88.0 (78.0–
At cath lab 59.0 (42.0–
Pre-discharge* 51.0 (36.0–
CD63
Baseline 19.0 (16.0–
At cath lab 12.0 (10.0–
Pre-discharge* 11.0 (10.0–
CD40L
Baseline 3.5 (3.0–4
At cath lab 3.1 (2.7–3
Pre-discharge* 3.0 (2.7–3
CD41 (GP IIb)
Baseline 655.0 (581.0
At cath lab 563.5 (484.0
Pre-discharge* 554.0 (475.5
Platelet function tests were available pre-discharge in 760 patients (n  525 wild-type homozyg
n 666 patients (n  465/n  201); data are expressed as median (interquartile range). p value
ADP  adenosine diphosphate; au  arbitrary units; GP  glycoprotein; RPA  residual platlthough the proportion of patients with RPA 14% had (ncreased in both genotypes after the first maintenance dose
t pre-discharge, a difference of 18.8 percentage points in
he proportion of patients with RPA 14% persisted
etween carriers of the *2 allele and wild-type homozygotes.
he higher on-treatment platelet reactivity in carriers of the
2 allele as compared with wild-type homozygotes was
aused by an attenuated platelet inhibition by clopidogrel,
ut not by differences in baseline platelet reactivity. This was
hown by light transmittance aggregometry after stimula-
ion with both 5 and 20 mol/l ADP. Flow-cytometry
nalysis of surface expression of platelet proteins after
timulation with ADP confirmed the results of light trans-
ittance aggregometry. In patients with at least 1
YP2C19*2 allele, surface expressions of P-selectin
YP2C19 Genotype
cording to CYP2C19 Genotype
CYP2C19 *1/*2 or *2/*2 (n  245)
p Valuenge Median Interquartile Range
48.0 (38.0–60.0) 0.106
23.0 (8.0–38.0) 0.001
11.0 (5.0–22.0) 0.001
51.6 (20.0–81.6) 0.001
74.5 (56.9–88.5) 0.001
74.0 (66.0–82.5) 0.125
50.0 (28.0–64.0) 0.001
31.0 (15.0–50.0) 0.001
32.9 (14.2–64.1) 0.001
58.1 (32.5–80.9) 0.001
109.0 (84.3–149.0) 0.600
44.0 (21.3–77.8) 0.001
35.0 (17.0–59.0) 0.001
90.0 (78.0–101.0) 0.669
75.5 (54.0–90.0) 0.001
63.0 (46.0–79.5) 0.001
20.0 (16.3–23.0) 0.378
14.0 (12.0–17.0) 0.001
13.0 (11.0–16.0) 0.001
3.5 (3.0–4.2) 0.845
3.2 (2.8–3.8) 0.013
3.2 (2.8–3.8) 0.010
) 665.5 (571.3–758.5) 0.408
) 608.5 (520.5–688.3) 0.001
) 581.0 (508.3–659.0) 0.003
d n  235 patients carrying at least 1 CYP2C19*2 allelic variant) and surface protein expression
n-Whitney U test between CYP2C19*1/*1 and CYP2C19*2 genotype.
regation.to C
s Ac
52)
tile Ra
57.0)
8.0)
4.0)
92.1)
94.3)
80.0)
56.0)
8.5)
83.9)
89.3)
147.0)
54.0)
36.0)
100.0)
79.0)
66.5)
23.0)
15.0)
14.0)
.3)
.6)
.5)
–736.0
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CYP2C19 and Antiplatelet Effect of Clopidogrel May 20, 2008:1925–34nd CD63 after loading with clopidogrel were significantly
igher than in wild-type homozygotes, both during PCI
nd at pre-discharge.
We did not determine plasma concentrations of the active
etabolite of clopidogrel (R130,964), which constitutes a
imitation of our study. Thus, we cannot provide direct
vidence for the relationship between a diminished systemic
vailability of the active metabolite and the blunted anti-
latelet effect of clopidogrel in patients with nonfunctioning
YP2C19. The chemical instability of the metabolite re-
uires extensive pre-analytical precautions and rapid chem-
cal derivatization after blood withdrawal, which cannot be
arranted in a study on large patient cohorts under clinical
onditions. Data from a case report describing a nonre-
ponder to clopidogrel treatment (31); the results of a
Figure 3 Cumulative Composite Incidence of Death and MI
Cumulative composite incidence of death and myocardial infarction (MI) from
pre-discharge to 1 year in the 2 strata defined by pre-discharge RPA. Abbrevia-
tions as in Figure 1.
Clinical Outcome According to Pre-Discharge RP
Table 3 Clinical Outcome According to Pre-
RPA <14%
(n  548)
Death or MI 11 (2.0)
Death 3 (0.5)
Nonfatal MI
ST-segment elevation MI 2 (0.4)
Non–ST-segment elevation MI 6 (1.1)
Target lesion reintervention 60 (10.9)
Any stent thrombosis 7 (1.3)
Definite or probable 5 (0.9)
Definite 2 (0.4)
Probable 3 (0.5)
Possible 2 (0.4)
Stent thrombosis was defined according to Academic Research Consor
ratios (HRs) (95% confidence intervals [CIs]) are based on the Cox pro
statistics.
Abbreviations as in Table 1.ose-response study investigating the antiplatelet effects of
ncreasing bolus doses of clopidogrel 300, 600, and 900 mg
32); and a recent study investigating antiplatelet effects of a
00-mg bolus dose of clopidogrel in healthy subjects (33)
rovide robust evidence that the antiplatelet effects of
lopidogrel in vivo are correlated to the systemic availability
f the active metabolite. Thus, it is reasonable to assume
hat a decrease in systemic exposure to the active compound
s the mechanism responsible for the attenuated efficacy of
lopidogrel in CYP2C19*2 patients.
Our findings expand the reports on attenuated antiplate-
et effects of clopidogrel in healthy volunteers carrying the
oss-of-function CYP2C19*2 allele (19,23) and, thus, add
ubstantial evidence for the involvement of CYP2C19 in the
ormation of the active metabolite of clopidogrel. Although
he pharmacologic activity of clopidogrel is significantly
ttenuated in patients carrying one CYP2C19*2 allele, these
atients and even CYP2C19*2 homozygous patients exhibit
ignificant antiplatelet effects of clopidogrel underlining the
ontribution of alternative metabolic pathways via different
embers of the CYP system for the formation of the active
etabolite.
otential clinical relevance in the setting of coronary
tent placement. The clinical relevance of the attenuation
f the antiplatelet effect of clopidogrel in carriers of the *2
llele is a key issue. To approach this issue, the principle
uestion has to be answered whether high on-clopidogrel
eactivity is, in fact, associated with poor clinical outcome
fter stent placement. Although we previously showed that
igh on-clopidogrel reactivity, as defined by RPA 14%, is
ssociated with a substantially increased 30-day risk of
ajor adverse cardiac events after PCI with stent placement
1), we intended to corroborate these findings by extension
f the follow-up to 1 year.
We found that the pre-discharge level of RPA in patients
n clopidogrel is a major determinant of the 1-year cardiac
utcome after PCI with stent placement. In patients who
id not achieve a pre-discharge RPA 14% after the first
arge RPA
RPA >14%
(n  217) HR (95% CI) p Value
13 (6.0) 3.0 (1.4–6.8) 0.004
7 (3.2) 6.0 (1.5–23.2) 0.003
2 (0.9) 2.6 (0.4–18.1) 0.33
4 (1.8) 1.7 (0.5–6.1) 0.40
26 (12.0) 1.1 (0.7–1.8) 0.67
10 (4.6) 3.7 (1.4–9.6) 0.008
8 (3.7) 4.1 (1.3–12.5) 0.01
1 (0.5) 1.3 (0.1–14.1) 0.84
7 (3.2) 5.9 (1.5–23.0) 0.01
2 (0.9) 2.6 (0.4–18.4) 0.34
iteria. Data are expressed as number of patients (percentage). Hazard
al hazards model, and the associated p values are based on log-rankA
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May 20, 2008:1925–34 CYP2C19 and Antiplatelet Effect of Clopidogrel5-mg maintenance dose of clopidogrel after loading with
00 mg the day before, the 1-year incidence of death and
I was increased by 3-fold compared with patients whose
PA fell below the cut point. The excess risk associated
ith high levels of RPA at pre-discharge was driven by a
ignificantly increased mortality and by a surplus of large
Is. Thus, our findings underscore the clinical relevance of
dequate RPA levels in the prevention of subsequent serious
ardiac complications. Further studies will clarify whether
ore intense therapy designed for correction of inadequate
uppression of platelet reactivity will improve outcome.
The impact of pre-discharge RPA on outcome differed
ubstantially depending on stent type. In patients having
eceived at least 1 drug-eluting stent who continued on
lopidogrel for 6 months, a pre-discharge RPA 14% was
articularly deleterious. In this subset, it conferred an almost
-fold increase in the risk of death and MI during the 1-year
ollow-up, as compared with a pre-discharge RPA 14%.
n patients who exclusively received bare-metal stents, we
lso found an increased risk with pre-discharge RPA14%,
ut the association between high pre-discharge RPA and
oor outcome was weaker than in the subset with drug-
luting stents and did not reach statistical significance.
hese findings support the generally accepted view that the
elayed vascular healing after drug-eluting stents necessi-
ates a more robust and sustained platelet inhibition than
hat needed after placement of bare-metal stents (34).
Although we were able to demonstrate that high on-
lopidogrel platelet reactivity is associated with poor clinical
utcome and that the presence of a *2 allele of CYP2C19
ncreases the propensity for high on-clopidogrel platelet
eactivity, we were unable to demonstrate the impact of the
2 allele of CYP2C19 on clinical outcome directly. The
Figure 4 Cumulative Composite Incidence of Death and
MI in Subsets With and Without Placement of DES
Cumulative composite incidence of death and MI from pre-discharge to 1 year
stratified by pre-discharge RPA in subsets with and without placement of drug-
eluting stents (DES). BMS  bare-metal stent; MI  myocardial infarction;
other abbreviations as in Figure 1.XCELSIOR trial was not powered to address this issueirectly. Given that a 100% difference in the proportion of
atients with RPA 14% was associated with a 3-fold risk
f death and MI during 1-year follow-up, it can be
stimated in the given setting that a 20% difference (as that
etween *2 allele carriers and non-carriers) would result in a
elative risk of 1.26. Thus, a substantially higher number of
atients would have been needed to demonstrate a direct
elation between the *2 allele of CYP2C19 and clinical
utcome in clopidogrel-treated patients having undergone
tent placement.
mplications. The results of our study identify a cohort
ith a genetic background that predisposes to attenuated
ntiplatelet effects of clopidogrel, which may expose patients
o an increased risk of thrombotic events. It is conceivable
hat the clinical impact of attenuated antiplatelet effects of
lopidogrel may be particularly prominent in patients with
igher risk, such as patients with acute coronary syndromes
12). Our study, however, demonstrates that even in pa-
ients considered to be at low to intermediate risk of cardiac
omplications after coronary stent placement, a high resid-
al platelet reactivity after administration of clopidogrel has
major impact on long-term outcome. Patients having
eceived a drug-eluting stent are particularly sensitive to
igh residual levels of platelet aggregation during treatment
ith clopidogrel, with an almost 8-fold increased risk of
eath and MI during the first year after stent placement.
It is unclear so far, if the antiplatelet effect of clopidogrel
n patients carrying the *2 allelic variant of CYP2C19 can be
mproved by administration of higher bolus and/or mainte-
ance doses of clopidogrel or if alternative treatment regi-
ens should be preferred. In vitro and in vivo studies
nvestigating the metabolism of the newly developed P2Y12-
eceptor antagonist prasugrel indicate that CYP3A and
YP2B6 provide the greatest contribution to the metabolic
ctivation of this new compound with less contributions
rom CYP2C9 and CYP2C19 (35). Given the susceptibility
f the thienopyridine metabolism to the highly polymorphic
YP system, genetic profiling may become a tool in
ailoring the choice of antiplatelet agent to the individual
atient’s needs. In this respect, our current study may help
esign a clinical relevant panel of polymorphic genes to be
ssessed.
eprint requests and correspondence: Dr. Dietmar Trenk,
erz-Zentrum Bad Krozingen, Suedring 15, D-79189 Bad Kroz-
ngen, Germany. E-mail: dietmar.trenk@herzzentrum.de.
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